Compare AMBQ & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | ORIC |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2025 | 2020 |
| Metric | AMBQ | ORIC |
|---|---|---|
| Price | $62.91 | $12.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $42.20 | $19.73 |
| AVG Volume (30 Days) | 374.6K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.97 | 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,514,000.00 | N/A |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.12 | $7.23 |
| 52 Week High | $91.61 | $14.93 |
| Indicator | AMBQ | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 47.09 |
| Support Level | $55.79 | $10.67 |
| Resistance Level | $68.15 | $12.57 |
| Average True Range (ATR) | 2.75 | 0.59 |
| MACD | 0.84 | -0.16 |
| Stochastic Oscillator | 59.61 | 26.36 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the power consumption challenges of general purpose and AI compute - especially at the edge. The company provides a full-stack solution encompassing tightly integrated hardware and software. Its solutions include a diverse family of systems-on-chip (SoCs) and the software required to enable on-chip AI processing, general compute, sensing, security, storage, wireless connectivity, and developed graphics.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.